CA2975952C - PANEL OF BIOMARKERS INTENDED FOR CANCER DETECTION - Google Patents

PANEL OF BIOMARKERS INTENDED FOR CANCER DETECTION

Info

Publication number
CA2975952C
CA2975952C CA2975952A CA2975952A CA2975952C CA 2975952 C CA2975952 C CA 2975952C CA 2975952 A CA2975952 A CA 2975952A CA 2975952 A CA2975952 A CA 2975952A CA 2975952 C CA2975952 C CA 2975952C
Authority
CA
Canada
Prior art keywords
mir
methylation
marker
cancer
hyal2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2975952A
Other languages
English (en)
French (fr)
Other versions
CA2975952A1 (en
Inventor
Barbara Burwinkel
Rongxi Yang
Andreas Schneeweiss
Original Assignee
Universitaet Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Heidelberg filed Critical Universitaet Heidelberg
Publication of CA2975952A1 publication Critical patent/CA2975952A1/en
Application granted granted Critical
Publication of CA2975952C publication Critical patent/CA2975952C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CA2975952A 2015-02-24 2016-02-24 PANEL OF BIOMARKERS INTENDED FOR CANCER DETECTION Active CA2975952C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15156389.7 2015-02-24
EP15156389 2015-02-24
PCT/EP2016/053813 WO2016135168A1 (en) 2015-02-24 2016-02-24 Biomarker panel for the detection of cancer

Publications (2)

Publication Number Publication Date
CA2975952A1 CA2975952A1 (en) 2016-09-01
CA2975952C true CA2975952C (en) 2025-02-06

Family

ID=52589264

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2975952A Active CA2975952C (en) 2015-02-24 2016-02-24 PANEL OF BIOMARKERS INTENDED FOR CANCER DETECTION

Country Status (16)

Country Link
US (1) US10941451B2 (cg-RX-API-DMAC7.html)
EP (1) EP3262190B1 (cg-RX-API-DMAC7.html)
JP (2) JP6807873B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170120124A (cg-RX-API-DMAC7.html)
CN (1) CN107406880A (cg-RX-API-DMAC7.html)
AU (1) AU2016223532B2 (cg-RX-API-DMAC7.html)
CA (1) CA2975952C (cg-RX-API-DMAC7.html)
DK (1) DK3262190T3 (cg-RX-API-DMAC7.html)
EA (1) EA037995B1 (cg-RX-API-DMAC7.html)
ES (1) ES2893297T3 (cg-RX-API-DMAC7.html)
HK (1) HK1246828A1 (cg-RX-API-DMAC7.html)
IL (1) IL253756B (cg-RX-API-DMAC7.html)
MX (1) MX386750B (cg-RX-API-DMAC7.html)
PL (1) PL3262190T3 (cg-RX-API-DMAC7.html)
UA (1) UA124612C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016135168A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018236065A1 (ko) * 2017-06-21 2018-12-27 사회복지법인 삼성생명공익재단 대장암 환자의 항암제 치료 반응성 예측용 마커
KR102100557B1 (ko) * 2017-06-21 2020-04-14 사회복지법인 삼성생명공익재단 대장암 환자의 항암제 치료 반응성 예측용 마커
JP6614630B2 (ja) * 2017-08-23 2019-12-04 国立研究開発法人国立がん研究センター 肝細胞癌のリスク評価方法
WO2019081507A1 (en) 2017-10-23 2019-05-02 Universität Heidelberg NEW MARKERS DERIVED FROM BLOOD FOR CANCER DETECTION
JP7326764B2 (ja) * 2018-03-09 2023-08-16 東ソー株式会社 腫瘍マーカーならびに腫瘍細胞を夾雑細胞と区別して回収および検出する方法
CA3127154A1 (en) * 2019-02-21 2020-08-27 Universitat Heidelberg Biomarker panel for diagnosis and prognosis of cancer
GB201906199D0 (en) * 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
CN110136776B (zh) * 2019-05-15 2021-04-20 深圳大学 一种从低质量核糖体印迹数据预测基因编码框的方法和系统
CN110269869B (zh) * 2019-07-30 2023-03-31 宁夏医科大学 一种以蜥蜴为主的抗肿瘤药物及验证方法
CN112176419B (zh) * 2019-10-16 2022-03-22 中国医学科学院肿瘤医院 一种检测ctDNA中肿瘤特异基因的变异和甲基化的方法
CN113186279B (zh) * 2020-01-14 2024-07-02 腾辰生物科技(上海)有限公司 用于辅助诊断癌症的透明质酸酶甲基化标志物及试剂盒
CN118460718A (zh) * 2020-01-15 2024-08-09 腾辰生物科技(上海)有限公司 一种用于辅助诊断食管癌的钙结合蛋白甲基化标志物
CN118360405A (zh) * 2020-01-19 2024-07-19 腾辰生物科技(上海)有限公司 一种甲基化标志物在辅助诊断食管癌中的应用
CN118460720A (zh) * 2020-02-04 2024-08-09 腾辰生物科技(上海)有限公司 一种辅助诊断食管癌的甲基化标志物
CN113215250B (zh) * 2020-02-04 2024-04-30 腾辰生物科技(上海)有限公司 一个基因的甲基化水平在辅助诊断癌症中的应用
CN113528635B (zh) * 2020-04-16 2024-06-11 腾辰生物科技(上海)有限公司 一种印记基因的甲基化作为心脑血管疾病早期诊断的标志物
US20230340607A1 (en) * 2020-07-13 2023-10-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for detecting gene fusions of rad51ap1 and dyrk4 and for diagnosing and treating cancer
CN114480630B (zh) * 2020-10-26 2024-09-06 腾辰生物科技(上海)有限公司 用于辅助诊断癌症的一种甲基化标志物
US20240093306A1 (en) * 2021-02-04 2024-03-21 The Cleveland Clinic Foundation Micro rna liver cancer markers and uses thereof
CN115341027B (zh) * 2021-05-13 2025-08-26 高飞 急性淋巴细胞白血病dna甲基化标志物及其应用
JP7143480B1 (ja) * 2021-06-10 2022-09-28 株式会社大一商会 遊技機
CN114875131A (zh) * 2022-04-24 2022-08-09 上海市东方医院（同济大学附属东方医院） 靶向膜蛋白甲基化作为印记基因综合征标志物的检测方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211606A1 (en) * 2002-05-10 2003-11-13 Isis Pharmaceuticals Inc. Antisense modulation of DYRK4 expression
WO2005007892A1 (en) * 2003-07-03 2005-01-27 Gentron, Llc Methods and systems for diagnosis of non-cenral nervous system (cns) diseases in cns samples
KR20070004725A (ko) * 2004-02-20 2007-01-09 더 리전츠 오브 더 유니버시티 오브 캘리포니아 타액 ｍＲＮＡ 프로파일링, 생물 마커 및 관련 방법 및부품 키트
CN104846092A (zh) * 2007-02-21 2015-08-19 奥斯陆大学医院Hf 新型癌症标记物
WO2009067655A2 (en) * 2007-11-21 2009-05-28 University Of Florida Research Foundation, Inc. Methods of feature selection through local learning; breast and prostate cancer prognostic markers
CN101245386A (zh) * 2008-03-26 2008-08-20 中南大学 用于多种肿瘤抑瘤基因检测的cDNA芯片
US7897356B2 (en) 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes
JP2011097833A (ja) * 2009-11-04 2011-05-19 Takeshi Zama 特定の遺伝子のメチル化の頻度を、頭頸部腫瘍のバイオマーカーとして使用する方法
JPWO2011105570A1 (ja) 2010-02-26 2013-06-20 シスメックス株式会社 生体試料中の癌細胞の存否を判定する方法、判定用分子マーカーおよびキット
WO2012174282A2 (en) 2011-06-16 2012-12-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
JP2013027387A (ja) * 2011-06-21 2013-02-07 Tohoku Univ 膵臓癌バイオマーカー
WO2012175562A2 (en) * 2011-06-21 2012-12-27 University Of Tartu Methylation and microrna markers of early-stage non-small cell lung cancer
US10316367B2 (en) * 2012-06-21 2019-06-11 Ruprecht-Karls-Universität Heidelberg Circulating miRNAs as markers for breast cancer
EP2682477A1 (en) * 2012-07-06 2014-01-08 National University of Ireland, Galway miR-181a and miR652 as oncologic biomarker of breast cancer
WO2014020048A1 (en) * 2012-07-31 2014-02-06 Ruprecht-Karls-Universität Heidelberg Hyal2 methylation and expression as a cancer marker
JP2014036637A (ja) * 2012-08-20 2014-02-27 Hitachi Chemical Co Ltd 癌の切除手術後の予後を判定するためのデータ分析方法

Also Published As

Publication number Publication date
EA037995B1 (ru) 2021-06-21
AU2016223532A1 (en) 2017-08-17
JP2018509934A (ja) 2018-04-12
UA124612C2 (uk) 2021-10-20
EP3262190B1 (en) 2021-09-01
WO2016135168A1 (en) 2016-09-01
IL253756B (en) 2021-04-29
HK1246828A1 (zh) 2018-09-14
EA201791578A1 (ru) 2018-02-28
CA2975952A1 (en) 2016-09-01
CN107406880A (zh) 2017-11-28
MX2017010836A (es) 2018-02-09
PL3262190T3 (pl) 2021-12-20
US10941451B2 (en) 2021-03-09
IL253756A0 (en) 2017-09-28
JP2021052777A (ja) 2021-04-08
DK3262190T3 (da) 2021-10-11
KR20170120124A (ko) 2017-10-30
ES2893297T3 (es) 2022-02-08
EP3262190A1 (en) 2018-01-03
MX386750B (es) 2025-03-19
BR112017018008A2 (pt) 2018-04-10
US20180245159A1 (en) 2018-08-30
AU2016223532B2 (en) 2021-07-01
JP6807873B2 (ja) 2021-01-13

Similar Documents

Publication Publication Date Title
CA2975952C (en) PANEL OF BIOMARKERS INTENDED FOR CANCER DETECTION
US12129522B2 (en) MicroRNA assay for detection and management of pancreatic cancer precursors
US20200157631A1 (en) CIRCULATING miRNAs AS MARKERS FOR BREAST CANCER
EP2873740A1 (en) Methods for the surveillance, diagnosis and screening of bladder cancer
JP2014036672A (ja) 新しい癌マーカー
US20220127678A1 (en) Biomarker panel for diagnosis and prognosis of cancer
AU2015317893A1 (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
CA3082391A1 (en) Non-coding rna for detection of cancer
US20120148561A1 (en) Use of runx3 and mir-532-5p as cancer markers and therapeutic targets
Sin et al. Down‐regulation of TROP‐2 predicts poor prognosis of hepatocellular carcinoma patients
WO2014020048A1 (en) Hyal2 methylation and expression as a cancer marker
ES2352777B1 (es) Metodo y kit para el pronostico del linfoma de celulas del manto
BR112017018008B1 (pt) Métodos in vitro de diagnóstico de câncer de mama (bc), para identificar um paciente como responsivo ou não responsivo a um tratamento de bc, uso de um kit e dispositivo para a identificação de bc

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210129

EEER Examination request

Effective date: 20210129

EEER Examination request

Effective date: 20210129

EEER Examination request

Effective date: 20210129

EEER Examination request

Effective date: 20210129

EEER Examination request

Effective date: 20210129

EEER Examination request

Effective date: 20210129

EEER Examination request

Effective date: 20210129

EEER Examination request

Effective date: 20210129